Biofrontera AG
BIFRF
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 345.97% | -77.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 345.97% | -77.00% | |||
| Cost of Revenue | 159.59% | -201.37% | |||
| Gross Profit | 48.58% | -17.35% | |||
| SG&A Expenses | -37.28% | 74.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 84.51% | -56.73% | |||
| Operating Income | 100.76% | -15.24% | |||
| Income Before Tax | 101.75% | -525.41% | |||
| Income Tax Expenses | -- | 52,750.00% | |||
| Earnings from Continuing Operations | 101.41% | -670.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,777.10% | 131.09% | |||
| EBIT | 100.76% | -15.24% | |||
| EBITDA | 104.66% | -22.58% | |||
| EPS Basic | 1,635.71% | 133.95% | |||
| Normalized Basic EPS | 101.73% | -535.70% | |||
| EPS Diluted | 1,635.71% | 133.95% | |||
| Normalized Diluted EPS | 101.73% | -535.70% | |||
| Average Basic Shares Outstanding | 0.56% | -1.46% | |||
| Average Diluted Shares Outstanding | 0.56% | -1.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||